# Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
Canonical URL: https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-announces-fda-acceptance-of-sp16-investigational-new-drug-application-for-the-treatment-of-chemotherapy-induced-pain-and-neuropathy
Ticker: VIRI
Company: Virios Therapeutics
Source: Virios Therapeutics
Published: 2026-04-15 13:00 EST
Original Source URL: https://ir.dwtx.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-20 12:30 EST — [Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026](https://biopharmsignal.com/news/VIRI/dogwood-enrolls-first-200-patients-in-ongoing-halneuron-phase-2b-chemotherapy-in-dd9f404d) — Source: Virios Therapeutics
- 2026-06-30 12:45 EST — [Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board](https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-appoints-iain-dukes-venture-partner-at-orbimed-as-chair-of--8101d663) — Source: Virios Therapeutics
- 2026-05-18 12:45 EST — [Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study](https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-announces-commencement-of-halneuronr-chemotherapy-induced-neuropathic-pain-phase-2b-long-term-extension-study) — Source: Virios Therapeutics
- 2026-05-14 12:30 EST — [Dogwood Therapeutics Announces First Quarter 2026 Financial Results](https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-announces-first-quarter-2026-financial-results) — Source: Virios Therapeutics
- 2026-05-07 12:30 EST — [Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026](https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026) — Source: Virios Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)